Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS<sup>G12C</sup>-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis

Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS<sup>G12C</sup>-Mutated Metastatic Colorectal Cancer—A Multicentre Propensity-Score-Matched Retrospective Analysis

Background: KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer (mCRC) has recently been recognized as a distinct druggable molecular entity; however, there are limited data on its sensitivity to standard chemotherapy. In the near future, the combination of chemotherapy plus a KRAS&...

Full description

Bibliographic Details
Main Authors: Vincenzo Formica, Cristina Morelli, Veronica Conca, Maria Alessandra Calegari, Jessica Lucchetti, Emanuela Dell’Aquila, Marta Schirripa, Marco Messina, Lisa Salvatore, Federica Lo Prinzi, Giovanni Dima, Giovanni Trovato, Silvia Riondino, Mario Roselli, Ferdinandos Skoulidis, Hendrik-Tobias Arkenau, Chiara Cremolini
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
KRAS<sup>G12C</sup> mutation
metastatic colorectal cancer
irinotecan
oxaliplatin
Online Access:https://www.mdpi.com/2072-6694/15/11/3064

Internet

https://www.mdpi.com/2072-6694/15/11/3064

Similar Items